Lanerkitug (BAY3375968) is a fully human monoclonal IgG1 anti-human CCR8 antibody. Lanerkitug selectively depletes human CCR8 + Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors [1] [2].
In Vivo, Lanerkitug shows a good safety profile in cynomolgus monkeys[2].
In Vitro, Lanerkitug (0.001 pM-10000 pM; 2-4 h) mediates potent Fc-dependent ADCC of human CCR8-expressing HEK293 cells and primary human activated Tregs (EC50 = 0.35-0.48 pM)[1]. Lanerkitug selectively deplets human CCR8+ Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP)[2].
References:
[1]. Roider H, et al. BAY 3375968: An afucosylated anti-CCR8 antibody depleting activated intratumoral regulatory T cells as a cancer immunotherapy[J]. Cancer Research, 2022, 82(12_Supplement): 2866-2866.
[2]. Roider HG, et al. Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody. Clin Exp Med. 2024;24(1):122. Published 2024 Jun 10.
In Vivo, Lanerkitug shows a good safety profile in cynomolgus monkeys[2].
In Vitro, Lanerkitug (0.001 pM-10000 pM; 2-4 h) mediates potent Fc-dependent ADCC of human CCR8-expressing HEK293 cells and primary human activated Tregs (EC50 = 0.35-0.48 pM)[1]. Lanerkitug selectively deplets human CCR8+ Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP)[2].
References:
[1]. Roider H, et al. BAY 3375968: An afucosylated anti-CCR8 antibody depleting activated intratumoral regulatory T cells as a cancer immunotherapy[J]. Cancer Research, 2022, 82(12_Supplement): 2866-2866.
[2]. Roider HG, et al. Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody. Clin Exp Med. 2024;24(1):122. Published 2024 Jun 10.